Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S7W-01864 · Session 7

What steps it plans to take to improve access to clinical trials for people affected by brain tumours.

Answered Asked by Martyn Day SNP Lodged 20 Jul 2026

The question

To ask the Scottish Government what steps it plans to take to improve access to clinical trials for people affected by brain tumours.

The answer

Answered by Maree Todd on 13 Aug 2026 · 24 days after it was lodged, on time

Within the Scottish Government policy responsibility for Health and Care Research sits with the Chief Scientist Office (CSO).NHS Research Scotland (NRS) is a partnership between the NHS Boards and CSO. NRS works to ensure that the NHS in Scotland provides the best environment to support clinical trials. The Scottish Government provides annual NRS Infrastructure support funding. The 2025-26 figure for this funding was £46.16 million.The above infrastructure includes the NRS Cancer Research Network that supports the set up and delivery of cancer clinical trials including in brain tumours (Cancer | NHS Research Scotland | NHS Research Scotland) – annual Scottish Government funding to the NRS Cancer Network is in the region of £1 million per annum. The NRS Cancer Network is currently supporting 10 brain tumour studies open to recruitment in the NHS in Scotland – these studies have recruited a total of over 120 patients to date.CSO co-funds in partnership with Cancer Research UK, the Adult Experimental Cancer Medicine Centres (ECMC's) in Edinburgh and Glasgow, and a Paediatric ECMC in Glasgow. These form part of a UK-wide ECMC Network that works to support the delivery of early phase cancer studies including in Brain Tumours (Edinburgh adult centre | Experimental cancer medicine centres) and (Glasgow adult centre | Experimental cancer medicine centres) – CSO’s annual contribution is approximately £470K.The VPAG Commercial Clinical Trials Investment Programme was agreed as part of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG). It aims to strengthen the UK’s global competitiveness in life sciences and support innovation led growth. The programme is supported by approximately £400 million of funding from the Association of the British Pharmaceutical Industry members.The clinical trials component of VPAG is intended to enhance capacity and delivery of commercial clinical research across the UK. Approximately £40 million from this element of the VPAG investment programme is expected to be invested in Scotland over the five year scheme. CSO has worked with NRS to configure this investment to maximise the opportunities for patients to participate in commercial clinical trials.This includes the setting up of 4 Commercial Research Delivery Centres (CRDC's)
- based in Aberdeen, Dundee, Edinburgh and Glasgow
- to accelerate and strengthen commercial clinical research delivery. It is anticipated that Cancer trials (including Brain Tumour trials) will represent around 50% of the commercial trial portfolio.

In the Official Report

No contribution in the Official Report cites S7W-01864 by reference.